Successful combination of anti-CD33 antibody (gemtuzumab ozogamicin) and minimal conditioning before second allografting in recurrent acute myeloid leukaemia.
Hänel
Mathias
M
Thiede
Christian
C
Helwig
Anett
A
Prange-Krex
Gabriele
G
Babatz
Jana
J
Haack
Michael
M
Kroschinsky
Frank
F
Fetscher
Sebastian
S
Ehninger
Gerhard
G
Bornhäuser
Martin
M
D000208:Acute Disease; D000328:Adult; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D005260:Female; D000079982:Gemtuzumab; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000601:surgery; D012086:Reoperation; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000079982:Gemtuzumab